Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics sees "statistically significant" improvement one year on

“Acarovac Plus bolsters our portfolio of allergy immunotherapy products on the market in Europe and we look forward to continued good growth.”
Dust mites close up
Over 20% of Europeans are allergic to dust mites.

Allergy Therapeutics plc (LON:AGY) reported statistically significant reduction in symptoms in patient studies to test the efficacy of its dust mite allergy immunotherapy treatment.

The allergy vaccines group published its one-year follow-up study of patients using Acarovac Plus, its flagship dust mite allergy vaccine.

A statistically significant reduction in symptom scores was observed at both follow-up visits (four weeks and one year), with a reduction of up to 50% in symptom scores recorded after one year.

Significant improvements in immunological markers were noted at the follow-up visits, said the group.

With over 20% of Europeans allergic to dust mites, sales of house dust mite immunotherapy are expected to increase rapidly over the coming years.

“Acarovac Plus bolsters our portfolio of allergy immunotherapy products on the market in Europe and we look forward to continued good growth,” said chief executive Manuel Llobet.

View full AGY profile View Profile

Allergy Therapeutics plc Timeline

Related Articles

picture of pregnant women
May 09 2017
Diclectin is entering a potential £250mln UK/European market with a differentiated product addressing an unmet need.
viagra2.jpg
September 07 2016
It means Futura now has a differentiated product in a market worth US$5bn that , currently dominated by top-selling drugs, such as Viagra and Cialis, that have limitations.
The Hydroponics Company: Access latest PPT from Proactive's CEO Sessions
May 19 2017
Dr Andrew Beehag talked medical cannabis products and pathways with investors.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use